- Research article
- Open Access
Inhibition of Pseudomonas aeruginosa with a recombinant RNA-based viral vector expressing human β-defensin 4
BMC Microbiology volume 14, Article number: 237 (2014)
Harassed with extensive epithelial burn wounds, patients can be affected by complications, such as infection, hypovolemic shock, hypothermia, and respiratory failure. Immediate first aid and followed supportive cares are critical for the prevention of severe complications. However, secondary bacterial infection is hard to be controlled in burn patients, and Pseudomonas aeruginosa (P. aeruginosa) is one of the top listed pathogens perturbing burn wounds beyond the antibiotics spectrum.
To find the way for efficacious protection from the pseudomonas-mediated complications in burn patients, we assessed the in vitro and in vivo inhibitory values of human β-defensin 4 (hBD4), which is known as a member of the cationic, antimicrobial peptides found in human cells of many kinds. The Newcastle disease virus (NDV) was used as a viral vector for the expression of hBD4 in burn wounds. Expressed from the recombinant NDV (rNDV-hBD4), hBD4 effectively inhibited the pseudomonal growths in cell culture media. In a mouse model, severely burn-injured skin was recovered by the direct installation of the rNDV-hBD4 infected cells in the burn wounds whereas that of control mice remained severely damaged.
We suggest that the application of hBD4 may protect burn patients from secondary pseudomonal infection and provide a therapeutic potential for burn wound treatment.
An estimated 450,000 burn injuries were treated in hospitals and clinics in the United States in 2011 . Approximately 10% of burn injury cases require hospitalization for intensive medical treatment, and bacterial infection is one of the major causes of burn-related deaths . Because thermal injury of the normal skin barrier results in depression of local and systemic immune responses and results in host protein leakage into necrotic tissues, pathogenic microbes efficiently proliferate and colonize in burn wound areas . Among the various species of bacteria isolated from burn wounds, P. aeruginosa represents one of the principal pathogens . Gram-negative, naturally antibiotic-resistant P. aeruginosa persistently infects burn wounds, delays wound recovery, and subsequently interferes with clinical therapies . Thus, it is important to both control P. aeruginosa complications in the early stages of burn injury and reduce the risk of septic shock in burn patients .
Management of burn wounds requires comprehensive measures. Fluid resuscitation, pain control, pulmonary care, nutritional support, surgical debridement, and other intensive treatments are important considerations for severe burn injuries ,. Topical or systemic applications of antimicrobial agents have also been shown to protect patients with burn wounds from subsequent bacterial infections. However, the therapeutic effects of antibiotics against bacterial invasion appear to be limited, especially in severe cases of burn injuries , and antibiotic use often induces complications involving the development of antibiotic-resistant strains . To be controlled, these resistant strains need even more and stronger measures of antibiotics, or damages may develop further into septic consequences. Controversy over antibiotics in burn patient treatments can be also seen in the fact that burn-injured children treated with antibiotics exhibit higher infection rates and poorer prognosis during sepsis than non-treated children . Moreover, in cases of patients with a burn injury of more than 40% of the total body surface area, subsequent secondary bacterial infections are difficult to be controlled with antibiotic intervention alone .
Found in vertebrates and invertebrates, defensins which are small, cysteine-rich antimicrobial peptides may be an alternative measure against antibiotics-resistant bacteria . Two main classes of defensins, α- and β-defensins, have been studied in the context of bacterial infections . Among the many subfamilies of β-defensins, we focused on human β-defensin 4 (hBD4), which can be found in testes, epithelial surfaces of thyroid glands, lungs, uterus, and kidneys, because it displayed a strong antimicrobial activity, especially against P. aeruginosa-. However, due to the relatively small size of the hBD4 molecule, a stable, high-yield delivery platform is required for the successful expression of the protein in target tissues . Recently, an adenovirus vector has been used to deliver human β-defensin 3 into normal human skin cells . However, use of the adenoviral vector has been criticized for poor gene delivery efficacy and safety issues ,. Anti-adenoviral patient antibodies might represent another hurdle preventing the clinical use of adenoviral vectors . Instead, we utilized a Paramyxoviridae avian Newcastle disease virus (NDV). The NDV has been recognized for its efficacy as a RNA viral vector not only for cancer therapies  but also for vaccine constructs . Approved safety and superior expression efficiency for the inserted foreign gene add another merit to the usefulness of the NDV vector in humans ,.
In this study, we present the feasibility of hBD4 for the protection of burn wounds from secondary pseudomonal manifestation. Inserted into the recombinant NDV construct, hBD4 was effectively delivered right into the burn-injured epithelial layer of mice, and promoted skin healing as complete as an unburned control even in the event of concurrent P. aeruginosa infection.
All animal procedures were conducted in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the Animal, Plant, and Fisheries Quarantine and Inspection Agency of Korea, and the experimental protocol was approved by the Institutional Animal Care and Use Committee of Hallym University (permit number: Hallym 2009-16).
Cells and viruses
Human lung epithelial A549, human laryngeal cancer HEp-2, Madin-Darby canine kidney (MDCK), and Madin-Darby bovine kidney (MDBK) cells were obtained from the American Type Culture Collection (ATCC; Manassas, VA). Primary human dermal fibroblast (HDF) cells were obtained from Modern Cell and Tissue Technologies (Seoul, Republic of Korea). Primary chicken embryo fibroblast (CEF) cells were established from fertile chicken eggs (9-10 days old). Cells were maintained in appropriate media and supplemented with 10% fetal bovine serum (FBS; Hyclone, Logan, UT), 100 U/ml penicillin, and 100 μg/ml streptomycin (Invitrogen, Carlsbad, CA).
Newcastle disease viruses were propagated in fertilized chicken eggs, and the viral presence was confirmed by hemagglutination assay (HA assay) using 0.5% (v/v) chicken erythrocytes and by sequence analysis using reverse transcriptase-PCR (RT-PCR) method.
Generation of recombinant NDV expressing hBD4 (rNDV-hBD4)
Human beta-defensin 4 (hBD4, NCBI accession: AJ314834) was amplified by PCR using testes cDNAs of the Human Total RNA Master Panel II (Clontech, Mountain view, CA). The sequences of primers are 5′-GCAGCCCCAGCATTATGCAG-3′ for sense and 5′-AAGCTACTGAGG TCCTACTT-3′ for anti-sense. After sequence confirmation, hBD4 was inserted into a specific restriction enzyme site, Sac II, between P and M genes of the NDV/Lasota (NCBI accession: JF950510) to generate the NDV-hBD4 plasmid (pNDV-hBD4). A set of NDV primers, 3013P (5′-GGCCGCGGTTAGAAAAAATACGGGTAGAACACTAGTCCGCCACCATGCAGAGACTTGTGCTG-3′) and 3430M (5′-GGCCGCGGAAATCAGGGTTTTGTACGATT-3′ for the anti-sense primer) were used to confirm pNDV-hBD4 construction. To rescue the recombinant NDV-hBD4 (rNDV-hBD4) virus, pNDV-hBD4 and supporting plasmids (pTM/Lasota-NP, -P, and -L) were transfected into A549 cells. 24 h later, transfected cells were co-cultured with CEF cells and incubated for 72 h at 37C, 5% CO2. Co-cultured cell supernatants were inoculated into fertilized chicken eggs for rNDV-hBD4 propagation.
GFP expression levels in various cells by recombinant NDV infection
A549, HEp-2, MDCK, MDBK, HDF, and CEF cells were seeded into 12-well plates at a density of 1.0 105 cells/well. With the approximately 80 ~ 90% confluent cell density, cells were infected with the recombinant NDV expressing green fluorescent protein (rNDV-GFP) at the same multiplicity of infection (MOI = 1) for 1 h. At 20 h post-infection (hpi), expressed GFP intensity was measured in triplicate.
Immunofluorescence confocal assay
To detect hBD4 expression, MDBK cells (1.0 105 cells per well) were cultured directly on the 24-well plates with glass coverslips and infected with the rNDV-hBD4 at an MOI of 1 for 1 h. At 12 hpi, Golgi stop protein transport inhibitor (BD Bioscience, San Jose, CA) was treated for 10 h. The cells were fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100 in PBS (PBST). After treated with PBST containing bovine serum albumin (PBST-BSA), NDV proteins and expressed hBD4 were detected primarily with polyclonal rabbit anti-NDV antibody and monoclonal mouse anti-hBD4 antibody, respectively. Then, Texas Red conjugated anti-rabbit antibody (Jackson ImmunoResearch, West Grove, PA) and Alexa 488 conjugated anti-mouse antibody (Invitrogen) were used as secondary antibodies. Hoechst 33258 (Invitrogen) was used for cell nucleus detection. The cells were imaged with a LSM 510 Meta LNO laser scanning microscope (Carl Zeiss, Jena, Germany) at Korea Basic Science Institute, Chuncheon, Korea. PBS-infected samples were used as a control.
Quantification of hBD4 with ELISA
To quantify hBD4 expression, MDBK cells were infected with the rNDV-hBD4 at an MOI of 10. At 24 hpi, cell supernatants were collected and prepared with the Centrifugal Filter (Millipore, Billerica, MA) for 1:10, 1:50, and 1:100 dilutions. hBD4 was then quantified in triplicate using polyclonal rabbit anti-hBD4 antibody and hBD4 peptide (Ana Spec, San Jose, CA) by enzyme-linked immunosorbent assay (ELISA). Cell culture media and rNDV-infected cell supernatants were used as controls.
In vitro inhibition efficacy of hBD4 against P. aeruginosa
MDBK cells were infected with the rNDV-hBD4 at an MOI of 10 for 1 h, and cell supernatants were collected at 12 and 24 hpi, respectively. The cell supernatants were then mixed with the same volume of P. aeruginosa (1 107 colony forming unit, cfu), which was obtained from Korean Culture Center for Microorganisms (Seoul, Republic of Korea; KCCM #11803; originated from MDB strain BU 277, ATCC#10145), and the mixtures were incubated at 37C, 5% CO2 for 6 h. Each mixture was spread onto LB agar plate and incubated at 37C, 5% CO2 for 16 h. P. aeruginosa colonies were counted using ChemiDoc XRS + (Bio-Rad, Hercules, CA). Cell culture media and rNDV-infected cell supernatants were used as controls.
In vivo inhibition efficacy of hBD4 against P. aeruginosa in burn-injured mouse skin
To make burn wounds, BALB/c mice (female, 6-week-old; NARA Biotech, Seoul, Republic of Korea) were anesthetized with the combination of xylazine (Narcoxyl, InterVet, The Netherlands) and zoletil (Zoletil 50, Virvac, France). Mice were then shaved on their back skin and burned with a square-shaped brass pole (16 mm 16 mm), being heated up to 100C and sterilized by an alcohol lamp for ~10 seconds. Right after burn procedure, the damaged skin of mice was infected with 50 μl of P. aeruginosa (1.0 104 cfu) via subcutaneous injection. For the expression of hBD4 in the burn wounds, MDBK cells were infected with the rNDV-hBD4 at an MOI of 10. At 12 hpi, the cells (~5 106 cells/mouse) were injected subcutaneously in the burn-injured, P. aeruginosa-infected skin of mice. The rNDV-infected MDBK cells were used for the treatment of a control mouse group. Mice were grouped as B (affected by burn), B/P (affected by burn and P. aeruginosa), B/P/N (affected by burn, P. aeruginosa, and rNDV-infected MDBK cell), and B/P/H (affected by burn, P. aeruginosa, and rNDV-hBD4-infected MDBK cell).
Statistical significance of GFP expression in cells (A549 vs. MDBK) and hBD4 expression (mock vs. rNDV-hBD4) was assessed by unpaired, two-tailed Students t test (*, p < 0.05; **, p < 0.01; and ***, p < 0.001). One-way ANOVA was applied to that of the colony count of P. aeruginosa (mock vs. rNDV-hBD4 or B/P vs. B/P/H) and skin recovery (B/P vs. B/P/H) (*, p < 0.05; **, p < 0.01; and ***, p < 0.001) results and confirmed by Tukeys multiple comparison test.
Generation of the rNDV-hBD4 virus
We first engineered a full-length plasmid of the NDV/Lasota strain (pNDV-Lasota) as a viral vector to express hBD4 (pNDV-hBD4) (Figure1A). Using the constructed pNDV-hBD4, we rescued the rNDV-hBD4 virus by plasmid-based reverse genetics as described previously . At 3 days post-transfection, HA positive samples were inoculated into fertilized chicken eggs for the propagation of the rNDV-hBD4 virus. To confirm the rescue of the rNDV-hDB4 virus, the egg allantoic fluids were used for the reverse transcriptase-PCR (RT-PCR). The hBD4-inserted T vector was used as a control. When using the hBD4 primer set (see Methods, Generation of recombinant NDV expressing hBD4 section), we detected the hBD4 nucleotide (nt) size of PCR products in two stocks of the rNDV-hBD4 virus and in the hBD4-inserted T vector control (Figure1B). However, the NDV 3013P and 3430M primers set yielded ~ 670 nt size RT-PCR products only in the rNDV-hBD4 samples due to the insertion of hBD4 between NDV P and M genes whereas only ~400 nt size product was detected in the wild-type (wt) NDV/Lasota virus (Figure1C). These results confirmed the right insertion of hBD4 into the NDV virus and the generation of the rNDV-hBD4 virus.
hBD4 expression from the rNDV-hBD4 virus
Burn-damaged skin may not support sustained hBD4 expression after the rNDV-hBD4 infection. Hence, we needed an intermediate host suitable for NDV infection and hBD4 expression. Using the rNDV-GFP virus, we screened various cells. Among 6 different cells tested (including CEF and HDF primary cells), MDBK cells expressed the strongest GFP signals (Figure2A). In the subsequent experiment only using MDBK and A549 cells, better GFP signals were determined in MDBK cells than in A549 cells (data not shown). Based on these results, we decided to use MDBK cells for the rNDV-hBD4 application against the pseudomonal attack in burn injury.
We then detected hBD4, expressed in MDBK cells after rNDV-hBD4 infection. To trap expressed hBD4 inside the cells, MDBK cells were treated with GolgiStop protein transport inhibitor. As seen in a PBS-infected control, hBD4 was barely detectable without GolgiStop treatment (Figure2B). However, GolgiStop treatment possibly inhibited hBD4 secretion into cell supernatants, and hBD4 was well detected along in the rNDV-hBD4-infected MDBK cells (Figure2B). These results indicated hBD4 could be expressed from rNDV-hDB4 virus infection in MDBK cells.
However, hBD4 was also detected in the mock-infected (~1.5 ng/ml) and rNDV-infected cell supernatants (Figure2C). As mentioned above, defensins can be found in various kinds of cells of living organisms. This might explain why hBD4 was detected in controls. To verify whether hBD4 expression was increased by rNDV-hBD4 virus infection, we determined the amount of NDV proteins using the same cell supernatants of Figure2C. In 10-, 50-, and 100-fold diluted cell supernatants, we detected the proportional increases of NDV proteins whereas no trace of NDV was detected in the mock-infected control (Figure2D). Considered together, these results indicate that hBD4 can be well expressed into the cell supernatants from rNDV-hBD4 virus infection in MDBK cells.
Inhibition efficacy of hBD4 against P. aeruginosa
Next, the in vitro inhibitory efficacy of hBD4 was evaluated against P. aeruginosa. To inhibit the growth of P. aeruginosa in cell culture media, we added the rNDV-hBD4-infected MDBK cell supernatants (MOI = 10, collected at 12 and 24 hpi) directly into the penicillin-free RPMI 1640 media, in which 107 cfu of P. aeruginosa would be growing. We then counted the number of colonies after spreading P. aeruginosa-hBD4 mixture onto penicillin-free LB agar plates. Surprisingly, 33.88% and 59.50% reduction rates in the number of P. aeruginosa colonies were determined with the respective 12 (4.00 103 cfu/ml) and 24 (2.45 103 cfu/ml) hpi supernatants of rNDV-hBD4-infected MDBK cells, compared with that (6.05 103 cfu/ml) of the mock-infected cell supernatant (Figure3A). This meant that more amounts of hBD4 might be expressed into the cell supernatant at 24 hpi than at 12 hpi and that hBD4 effectively inhibited the growth of P. aeruginosa.
To assess the in vivo inhibition efficacy of hBD4 against P. aeruginosa in the burn wounds, we used a surrogate burn injury mouse model. Mice were grouped as B (burned, n = 6), B/P (burned and P. aeruginosa-infected, n = 6), B/P/N (burned, P. aeruginosa-infected, and rNDV-MDBK injected, n = 6), and B/P/H (burned, P. aeruginosa-infected, and rNDV-hBD4-MDBK injected, n = 6). Normal mice treated with PBS represented the control group (n = 2, data not shown). During 21 days of observation, mice in the B group experienced severe skin injuries (Figure3B and C) and exhibited less physical activity, including reduced drinking and eating habits (data not shown). More severe skin damage was observed in the B/P mice (Figure3B and C). Their burn wounds were larger than those of the B group and were colonized with the greatest number (2.44 103 cfu/ml) of P. aeruginosa (Figure3B). Mice treated with the rNDV-infected MDBK cells were also colonized with a similar number (2.43 103 cfu/ml) of P. aeruginosa and experienced almost the same burn and bacterial infection sequelae as seen in those of the B/P group (Figure3B and C). However, the B/P/H mice, which were treated with rNDV-hBD4-infected MDBK cells, showed the most rapid skin recovery (Figure3B and C). Compared with the B, B/P, and B/P/N mice, P. aeruginosa was barely detected in the injured skin of the B/P/H mice (1.80 102 cfu/ml; p < 0.001) (Figure3B). At 21 days post-burn, only small skin contractures remained in the B/P/H mice as burn scars, and their skin had recovered as completely as the control mice (Figure3B and C). These results suggest that hBD4 expressed from rNDV protects burn wounds from subsequent P. aeruginosa infection.
hBD4 is a known antimicrobial peptide -,. However, it is difficult to utilize such a small peptide in currently available expression systems. We solved this problem by using the NDV vector. The NDV has been previously described as a highly useful vector for its oncolytic property in cancer therapy, stable expression efficiency as a vaccine platform, and relative safety in human applications because its RNA genome was not able to integrate into DNA chromosome ,. These features make the NDV a better candidate than any other viral vectors in future clinical purposes.
Additionally, NDV itself has been known as a strong immune inducer . However, treatment with NDV-infected MDBK cells did not benefit the burn-injured and subsequently P. aeruginosa-infected skin of mice in our model (Figure3B and C). In our animal model, we complicated the burn wounds with P. aeruginosa infection, and only the mice treated with rNDV-hBD4-infected MDBK cells overcame the supplementary pseudomonal exacerbation (Figure3B and C). The actual P. aeruginosa colony number was also extremely reduced only in the B/P/H mice (Figure3B). With evident efficacy against P. aeruginosa (Figure3A), these results imply that hBD4 can inhibit the growth of P. aeruginosa and intensify the rNDV-hBD4 effectiveness in burn wound therapy against the secondary bacterial complications.
MDBK cell-based application of hBD4 may be rejected for clinical application in humans. Due to this limitation, we also included human-origin cells including A549, HEp-2, and HDF cells in the initial test to select the best-fit cell candidate for the NDV-foreign gene expression (Figure2A). However, all these human cells were insufficient for foreign gene expression, compared with MDBK cells, and excluded in further analysis. In this screening process, the rNDV-GFP virus which is very sensitive to the interferon (IFN) activation was used because the GFP expression can be dependent on the IFN level synthesized in the infected cells. Therefore, the GFP intensity might determine which cell line could be suitable for the foreign gene expression from the rNDV.
The direct application of hBD4 expression plasmid or rNDV-hBD4 virus into the burn-injured skin layers may be also considered. However, burn-injured skin may not effectively support hBD4 expression and may require aseptic surgical debridement for normal skin regeneration or replacement surgery . Also, in severe cases of burn injury, the dermal skin layer can be affected, and destructions in nerves and blood vessels may result in subsequent bacterial colonization in the burn wounds . Hence, we used an intermediate host, the MDBK cells, to express hBD4 in burn-injured skin layers. For the application of rNDV-hBD4 virus in human burn injuries, NDV-susceptible human cells or synthetic tissue scaffolds harboring them may need to be engineered for efficient hBD4 expression in burn wounds.
Herein, we evaluated the therapeutic efficacy of the rNDV-hBD4 virus against P. aeruginosa infection in burn wounds. As an alternative clinical measure in burn wound remedies, hBD4 was applied to protect the burned skin of mice from P. aeruginosa complication, resulting in marked skin recovery. Although suitable cell lines or any equivalents, in addition to MDBK cells, should be further evaluated for the clinical application of rNDV-hBD4 in severe cases of burn injuries in humans, our results potentiate the therapeutic index of hBD4 and the use of the NDV vector in human cases of burn injury.
M-SP conceived and supervised this study. SP, JIK, and IL carried the molecular work. SP, JIK, IL, J-YB, M-WH, DK, S-IJ, HK participated cell-based and mice experiments. SP, JIK, IL, and M-SP analyzed the data and drafted the manuscript. MSP, H-JK, J-WS, YSC, and WC provided reagents and reviewed the manuscript. All authors read and approved the final manuscript.
Newcastle disease virus
Human β-defensin 4
Green fluorescent protein
Colony forming unit
American Burn Association: Burn incidence and treatment in the US: 2013 Fact Sheet.., [http://www.ameriburn.org/resources_factsheet.php]
Centers for Disease Control and Prevention (CDC): Emergency preparedness and response. Mass casualties: Burns.., [http://emergency.cdc.gov/masscasulaties/burns.asp]
Church D, Elsayed S, Reid O, Winston B, Lindsay R: Burn wound infections. Clin Microbiol Rev. 2006, 19 (2): 403-434. 10.1128/CMR.19.2.403-434.2006.
Guggenheim M, Zbinden R, Handschin AE, Gohritz A, Altintas MA, Giovanoli P: Changes in bacterial isolates from burn wounds and their antibiograms: a 20-year study (1986-2005). Burns. 2009, 35 (4): 553-560. 10.1016/j.burns.2008.09.004.
Singer AJ, McClain SA: Persistent wound infection delays epidermal maturation and increases scarring in thermal burns. Wound Repair Regen. 2002, 10 (6): 372-377. 10.1046/j.1524-475X.2002.10606.x.
Fitzwater J, Purdue GF, Hunt JL, OKeefe GE: The risk factors and time course of sepsis and organ dysfunction after burn trauma. J Trauma. 2003, 54 (5): 959-966. 10.1097/01.TA.0000029382.26295.AB.
Torpy JM, Lynm C, Glass RM: JAMA patient page. Burn injuries. JAMA. 2009, 302 (16): 1828-10.1001/jama.302.16.1828.
WHO: Surgical care at district hospital: 5.3 Burns. Accessed through ., [http://www.who.int/surgery/publications/en/SCDH.pdf]
Brown TP, Cancio LC, McManus AT, Mason AD: Survival benefit conferred by topical antimicrobial preparations in burn patients: a historical perspective. J Trauma. 2004, 56 (4): 863-866. 10.1097/01.TA.0000044565.69410.95.
Altoparlak U, Erol S, Akcay MN, Celebi F, Kadanali A: The time-related changes of antimicrobial resistance patterns and predominant bacterial profiles of burn wounds and body flora of burned patients. Burns. 2004, 30 (7): 660-664. 10.1016/j.burns.2004.03.005.
Ergun O, Celik A, Ergun G, Ozok G: Prophylactic antibiotic use in pediatric burn units. Eur J Pediatr Surg. 2004, 14 (6): 422-426. 10.1055/s-2004-821065.
Rafla K, Tredget EE: Infection control in the burn unit. Burns. 2011, 37 (1): 5-15. 10.1016/j.burns.2009.06.198.
Ganz T, Selsted ME, Szklarek D, Harwig SS, Daher K, Bainton DF, Lehrer RI: Defensins. Natural peptide antibiotics of human neutrophils. J Clin Invest. 1985, 76 (4): 1427-1435. 10.1172/JCI112120.
Menendez A, Brett Finlay B: Defensins in the immunology of bacterial infections. Curr Opin Immunol. 2007, 19 (4): 385-391. 10.1016/j.coi.2007.06.008.
Garcia JR, Krause A, Schulz S, Rodriguez-Jimenez FJ, Kluver E, Adermann K, Forssmann U, Frimpong-Boateng A, Bals R, Forssmann WG: Human beta-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity. Faseb J. 2001, 15 (10): 1819-1821.
Supp DM, Gardner J, Klingenberg JM, Neely AN: Antibiotic resistance in clinical isolates of Acinetobacter baumannii, Pseudomonas aeruginosa, and Staphylococcus aureus does not impact sensitivity to human beta defensin 4. Burns. 2009, 35 (7): 949-955. 10.1016/j.burns.2009.02.016.
Smiley AK, Gardner J, Klingenberg JM, Neely AN, Supp DM: Expression of human beta defensin 4 in genetically modified keratinocytes enhances antimicrobial activity. J Burn Care Res. 2007, 28 (1): 127-132. 10.1097/BCR.0b013E31802C88FD.
Wei Q, Kim YS, Seo JH, Jang WS, Lee IH, Cha HJ: Facilitation of expression and purification of an antimicrobial peptide by fusion with baculoviral polyhedrin in Escherichia coli. Appl Environ Microbiol. 2005, 71 (9): 5038-5043. 10.1128/AEM.71.9.5038-5043.2005.
Suzuki Y, Inokuchi S, Takazawa K, Umezawa K, Saito T, Kidokoro M, Tanaka M, Matsuzawa H, Inoue S, Tuchiya I, Ando K: Introduction of human beta-defensin-3 into cultured human keratinocytes and fibroblasts by infection of a recombinant adenovirus vector. Burns. 2011, 37 (1): 109-116. 10.1016/j.burns.2010.08.004.
Benihoud K, Yeh P, Perricaudet M: Adenovirus vectors for gene delivery. Curr Opin Biotechnol. 1999, 10 (5): 440-447. 10.1016/S0958-1669(99)00007-5.
Yang Y, Li Q, Ertl HC, Wilson JM: Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses. J Virol. 1995, 69 (4): 2004-2015.
McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR: HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet. 2008, 372 (9653): 1894-1905. 10.1016/S0140-6736(08)61592-5.
Zamarin D, Vigil A, Kelly K, Garcia-Sastre A, Fong Y: Genetically engineered Newcastle disease virus for malignant melanoma therapy. Gene Ther. 2009, 16 (6): 796-804. 10.1038/gt.2009.14.
Park MS, Steel J, Garcia-Sastre A, Swayne D, Palese P: Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease. Proc Natl Acad Sci U S A. 2006, 103 (21): 8203-8208. 10.1073/pnas.0602566103.
Schmidt CS, White CJ, Ibrahim AS, Filler SG, Fu Y, Yeaman MR, Edwards JE, Hennessey JP: NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine. 2012, 30 (52): 7594-7600. 10.1016/j.vaccine.2012.10.038.
Gao Q, Park MS, Palese P: Expression of transgenes from newcastle disease virus with a segmented genome. J Virol. 2008, 82 (6): 2692-2698. 10.1128/JVI.02341-07.
Nakaya T, Cros J, Park MS, Nakaya Y, Zheng H, Sagrera A, Villar E, Garcia-Sastre A, Palese P: Recombinant Newcastle disease virus as a vaccine vector. J Virol. 2001, 75 (23): 11868-11873. 10.1128/JVI.75.23.11868-11873.2001.
Niyonsaba F, Ogawa H: Protective roles of the skin against infection: implication of naturally occurring human antimicrobial agents beta-defensins, cathelicidin LL-37 and lysozyme. J Dermatol Sci. 2005, 40 (3): 157-168. 10.1016/j.jdermsci.2005.07.009.
Smyth MJ, Hayakawa Y, Takeda K, Yagita H: New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer. 2002, 2 (11): 850-861. 10.1038/nrc928.
Nusbaum AG, Gil J, Rippy MK, Warne B, Valdes J, Claro A, Davis SC: Effective method to remove wound bacteria: comparison of various debridement modalities in an in vivo porcine model. J Surg Res. 2012, 176 (2): 701-707. 10.1016/j.jss.2011.11.1040.
Deitch EA, Dobke M, Baxter CR: Failure of local immunity. A potential cause of burn wound sepsis. Arch Surg. 1985, 120 (1): 78-84. 10.1001/archsurg.1985.01390250070011.
This study was supported by grants from the Korea Healthcare Technology R&D Project of the Ministry of Health & Welfare, Republic of Korea (Grant No.: A084589) and the TEPIK (Transgovernmental Enterprise for Pandemic Influenza in Korea) (Grant No.: A103001). We would like to thank Drs. Peter Palese and Adolfo Garca-Sastre (Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY) for providing us with plasmids for the reverse genetics system.
The authors declare that they have no competing interests.